# Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

> **NCT02452463** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 8 (actual)

## Conditions studied

- Lung Non-Squamous Non-Small Cell Carcinoma
- Radiation-Induced Pneumonitis
- Stage II Lung Non-Small Cell Cancer AJCC v7
- Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Nintedanib
- **OTHER:** Placebo
- **PROCEDURE:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02452463
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-29
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-06-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2020-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452463, "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02452463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*